Plus Therapeutics regains Nasdaq minimum equity compliance after private placement

PLUS THERAPEUTICS, INC.

Received Nasdaq letter dated March 7, 2025 confirming compliance with minimum stockholders' equity requirement (Rule 5550(b)(1)).
Compliance achieved via private placement disclosed on March 4, 2025; escrow funds now released to the company.
Subject to Mandatory Panel Monitor until March 7, 2026; any future non-compliance triggers immediate delisting without cure period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.